ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 599,51
0,37%
Dow Jones
38 778,10
0,49%
DAX
18 131,73
0,32%
Brent Oil
83,595
-0,36%
Bitcoin
65 445,84
-1,56%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Rigel Pharmaceuticals Inc (RIGL)

  7. Rigel Pharmaceuticals Inc (RIGL) Actualités

RIGL

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RIGL
DateHeureSourceTitreSymboleSociété
14/06/202409h05PR Newswire (US)Rigel Announces Five Presentations at the EHA2024 Hybrid CongressNASDAQ:RIGLRigel Pharmaceuticals Inc
03/06/202414h13PR Newswire (US)Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual MeetingNASDAQ:RIGLRigel Pharmaceuticals Inc
30/05/202414h05PR Newswire (US)Rigel to Present at the Jefferies Global Healthcare ConferenceNASDAQ:RIGLRigel Pharmaceuticals Inc
30/05/202401h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
29/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
23/05/202423h00PR Newswire (US)Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid CongressNASDAQ:RIGLRigel Pharmaceuticals Inc
07/05/202422h01PR Newswire (US)Rigel Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
30/04/202414h05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
10/04/202422h30PR Newswire (US)Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:RIGLRigel Pharmaceuticals Inc
04/04/202414h05PR Newswire (US)Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaNASDAQ:RIGLRigel Pharmaceuticals Inc
12/03/202413h05PR Newswire (US)Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerNASDAQ:RIGLRigel Pharmaceuticals Inc
05/03/202422h06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RIGLRigel Pharmaceuticals Inc
05/03/202422h01PR Newswire (US)Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
27/02/202414h05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
22/02/202413h50PR Newswire (US)Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®NASDAQ:RIGLRigel Pharmaceuticals Inc
14/02/202420h30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RIGLRigel Pharmaceuticals Inc
08/01/202414h05PR Newswire (US)Rigel Pharmaceuticals Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
04/01/202414h05PR Newswire (US)Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in GliomaNASDAQ:RIGLRigel Pharmaceuticals Inc
03/01/202414h05PR Newswire (US)Rigel to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RIGLRigel Pharmaceuticals Inc
08/12/202314h05PR Newswire (US)Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other CancersNASDAQ:RIGLRigel Pharmaceuticals Inc
07/11/202322h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RIGLRigel Pharmaceuticals Inc
07/11/202322h01PR Newswire (US)Rigel Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
06/11/202314h05PR Newswire (US)Rigel to Present at the Jefferies London Healthcare ConferenceNASDAQ:RIGLRigel Pharmaceuticals Inc
02/11/202314h27PR Newswire (US)Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and ExpositionNASDAQ:RIGLRigel Pharmaceuticals Inc
31/10/202313h05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
11/10/202314h05PR Newswire (US)Rigel Announces Presentation at the Upcoming IDWeek 2023NASDAQ:RIGLRigel Pharmaceuticals Inc
20/09/202314h05PR Newswire (US)Rigel to Present at the 2023 Cantor Global Healthcare ConferenceNASDAQ:RIGLRigel Pharmaceuticals Inc
30/08/202314h05PR Newswire (US)Rigel to Participate in Upcoming September Investor ConferencesNASDAQ:RIGLRigel Pharmaceuticals Inc
01/08/202322h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RIGLRigel Pharmaceuticals Inc
01/08/202322h01PR Newswire (US)Rigel Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RIGL

Dernières Valeurs Consultées

NYSE
KO
Coca Cola
EU
EN
Bouygues
EU
CAP
Capgemini
NYSE
DIS
Walt Disney
NYSE
MCD
McDonalds
SPI
SP500
S&P 500
NYSE
MRK
Merck
EU
AI
Air Liquide
NYSE
NKE
Nike
EU
PX4
SBF 120
NYSE
JPM
JP Morgan Chase
EU
GLE
Societe Generale
EU
ACA
Credit Agricole
EU
VIV
Vivendi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés